slotkoers
Korea S.E.
00:00:00 23-03-2023
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
6.680
KRW
|
-29,91%
|
|
-.--%
|
-.--%
|
Fiscaal tijdperk: december |
2018
|
2020
|
2021
|
2022
|
2023
|
---|
Marktkapitalisatie
1 |
170.522
|
1.540.437
|
757.487
|
434.397
|
244.941
|
Bedrijfswaarde
1 |
133.693
|
1.507.707
|
717.004
|
482.529
|
289.701
|
K/w-verhouding
|
-17,2
x
|
-87,9
x
|
-26,2
x
|
-4,02
x
|
-7,51
x
|
Dividendrendement
|
-
|
-
|
-
|
-
|
-
|
Marktkapitalisatie/omzet
|
37,8
x
|
2.023
x
|
196
x
|
18,8
x
|
13
x
|
Bedrijfswaarde/omzet
|
29,6
x
|
1.980
x
|
185
x
|
20,8
x
|
15,4
x
|
Bedrijfswaarde/EBITDA
|
-37,2
x
|
-91
x
|
-27
x
|
-7,68
x
|
-18,4
x
|
Bedrijfswaarde/FCF
|
-5,75
x
|
-
|
-31
x
|
-9,62
x
|
-32,6
x
|
FCF Yield
|
-17,4%
|
-
|
-3,22%
|
-10,4%
|
-3,06%
|
Price to Book
|
4,76
x
|
20,1
x
|
10,1
x
|
41,5
x
|
-10
x
|
Aantal aandelen (in duizenden)
|
30.450
|
32.740
|
34.668
|
36.200
|
36.668
|
Referentieprijs
2 |
5.600
|
47.050
|
21.850
|
12.000
|
6.680
|
Datum van publicatie
|
14/03/19
|
22/03/22
|
22/03/22
|
23/03/23
|
21/03/24
|
Fiscaal tijdperk: december |
2018
|
2020
|
2021
|
2022
|
2023
|
---|
Omzet
1 |
4.512
|
761,6
|
3.872
|
23.158
|
18.863
|
EBITDA
1 |
-3.595
|
-16.573
|
-26.589
|
-62.822
|
-15.761
|
Bedrijfsresultaat (EBIT)
1 |
-4.102
|
-17.612
|
-28.050
|
-68.017
|
-20.711
|
Operationele Marge
|
-90,92%
|
-2.312,53%
|
-724,36%
|
-293,7%
|
-109,8%
|
Resultaat voor belastingen (EBT)
1 |
-6.651
|
-17.937
|
-29.682
|
-75.018
|
-34.007
|
Nettowinst (verlies)
1 |
-6.698
|
-17.248
|
-28.069
|
-75.159
|
-32.571
|
Nettomarge
|
-148,45%
|
-2.264,83%
|
-724,84%
|
-324,54%
|
-172,67%
|
WPA
2 |
-325,0
|
-535,3
|
-833,9
|
-2.985
|
-889,4
|
Free Cash Flow
1 |
-23.266
|
-
|
-23.098
|
-50.139
|
-8.879
|
FCF-marge
|
-515,61%
|
-
|
-596,48%
|
-216,5%
|
-47,07%
|
Kasstroomconversie (ebitda)
|
-
|
-
|
-
|
-
|
-
|
Kasstroomconversie (nettowinst)
|
-
|
-
|
-
|
-
|
-
|
Dividend per aandeel
|
-
|
-
|
-
|
-
|
-
|
Datum van publicatie
|
14/03/19
|
22/03/22
|
22/03/22
|
23/03/23
|
21/03/24
|
Fiscaal tijdperk: december |
2018
|
2020
|
2021
|
2022
|
2023
|
---|
Nettoschuldpositie
1 |
-
|
-
|
-
|
48.131
|
44.760
|
Nettokaspositie
1 |
36.829
|
32.730
|
40.483
|
-
|
-
|
Hefboom (schuld/ebitda)
|
-
|
-
|
-
|
-0,7662
x
|
-2,84
x
|
Free Cash Flow
1 |
-23.266
|
-
|
-23.098
|
-50.139
|
-8.879
|
ROE (netto-inkomsten/eigen vermogen)
|
-101%
|
-
|
-49,5%
|
-176%
|
433%
|
ROA (netto-inkomsten/totale activa)
|
-10,6%
|
-
|
-18,4%
|
-39,6%
|
-22,5%
|
Totale activa
1 |
63.257
|
-
|
152.387
|
189.659
|
144.516
|
Nettoactief per aandeel
2 |
1.177
|
2.338
|
2.153
|
289,0
|
-667,0
|
Cashflow per aandeel
2 |
32,30
|
1.752
|
2.000
|
401,0
|
39,60
|
Capex
1 |
665
|
1.208
|
4.590
|
17.649
|
64,5
|
Capex/omzet
|
14,73%
|
158,62%
|
118,52%
|
76,21%
|
0,34%
|
Datum van publicatie
|
14/03/19
|
22/03/22
|
22/03/22
|
23/03/23
|
21/03/24
|
|
Vaira. 1 jan.
|
Kapi.
|
---|
| -.--% | 182 mln. | | +9,42% | 115 mld. | | +11,84% | 106 mld. | | -1,05% | 21,96 mld. | | -14,15% | 21,84 mld. | | -5,29% | 19,21 mld. | | -4,16% | 18,08 mld. | | -38,29% | 17,71 mld. | | +7,99% | 14,32 mld. | | +36,24% | 12,42 mld. |
Biotherapeutische geneesmiddelen
|